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Le particelle simil-virali (virus-like particles, VLPs) sono candidati molto 
promettenti per lo sviluppo di nuovi vaccini. Gli approcci per la produzione in larga 
scala di HIV-1 Gag VLPs si sono focalizzati principalmente nel sistema di 
espressione basato sui baculovirus. In questo lavoro, le HIV-1 Gag VLPs sono state 
prodotte utilizzando un protocollo di espressione transiente, precedentemente 
sviluppato e ottimizzato dal gruppo di ricerca, in coltura in sospensione di cellule 
di mammifero. Lo scopo di questo lavoro è di studiare le principali variabili presenti 
nel processo per capire quale effetto possano avere sulla trasfezione transiente delle 
cellule e sulla produzione stessa delle VLPs. 
 
Per facilitare la quantificazione delle VLPs, la proteina Gag viene espressa in 
fusione con la eGFP (enhanced Green Fluorescence Protein), generando così VLPs 
fluorescenti che possono essere quantificate per fluorimetria. Da studi precedenti 
eseguiti dal gruppo di ricerca, la grande maggioranza delle Gag-eGFP prodotte e 
presenti nel sopranatante della coltura sono correttamente assemblate in VLPs le 
quali mostrano la morfologia e le dimensioni previste, simili a quelle delle particelle 
virali immature dell’HIV-1. 
 
Il medium di coltura utilizzato è stato precedentemente ottimizzato per lo scopo, 
utilizzando il disegno di esperimenti (Design of Experiments, DoE). Il risultato è un 
medium di coltura supplementato con componenti di derivazione non-animale i 
quali comprendono proteine ricombinanti e lipidi sintetici in grado di aumentare la 
crescita cellulare e la produzione delle VLPs. Le cellule utilizzate sono una linea di 
cellule di rene di embrione umano (Human Embryonic Kidney 293, HEK293) che, 
in queste condizioni, crescono fino a una concentrazione di 4,8 milioni di cellule 
per ml se coltivate in batch. 
 
La migliore performance di produzione si ottiene quando le cellule sono trasfettate 
durante la loro fase di crescita esponenziale, con ricambio del medium di coltura 
con medium fresco al momento della trasfezione ed utilizzando concentrazioni 
standard di DNA plasmidico e polietilienimina (PEI). 
Utilizzando questo metodo, mediamente, la metà delle cellule in coltura viene 
trasfettata positivamente e vengono prodotti circa 2,7 miliardi di VLPs per ml. Il 
problema intrinseco del metodo consiste nella variabilità dell’efficienza di 
trasfezione che porta anche ad una variabilità nella quantità di produzione delle 
VLPs. In questo lavoro, i risultati ottenuti mantengono questa tendenza. Grazie a 
una migliore comprensione delle variabili presenti, è possibile ridurre la variabilità 
osservata ed aumentare la produttività. 
 
Le variabili testate sono state diverse: variabili che influenzano la formazione dei 
poliplessi di DNA e PEI, altre che influenzano la procedura di trasfezione ed anche 
variabili che non dipendono dal protocollo di trasfezione. Per quanto riguarda la 
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formazione dei poliplessi, è stato studiato l’effetto dell’utilizzo di medium 
supplementato come solvente per la soluzione di DNA e PEI comparato con 
l’utilizzo di medium non supplementato; l’effetto della temperatura di tale medium 
e l’effetto del “vortex-step”. Riguardo la procedura di trasfezione sono stati studiati 
l’effetto dello stress cellulare dovuto al ricambio di medium e l’effetto dell’età delle 
beute utilizzate per il coltivo in batch. Da ultimo si è studiato l’effetto del passo 
cellulare, della concentrazione e della fase del ciclo cellulare al momento della 
trasfezione. 
 
Per studiare l’effetto della concentrazione cellulare sono stati adattati metodi di 
concentrazione e metodi di trasfezione alternativi. Mentre, per studiare l’effetto del 
ciclo cellulare sono state ottenute colture cellulari sincronizzate. Per raggiungere 
questo scopo due composti antineoplastici sono stati utilizzati. Di questi è stata 
studiata la tossicità, con saggi MTT, e il potere antineoplastico, grazie alla 
citometria di flusso. 
 
Per conoscere i tempi di trasfezione è stata effettuata una ricerca bibliografica i cui 
risultati hanno permesso di trasfettare con le tempistiche corrette le colture 
sincronizzate ottenute. 
 
Grazie agli studi effettuati è stato possibile concludere che il protocollo di 
trasfezione è robusto e non influenzato dai fattori operativi. Inoltre, è stato possibile 
definire un effetto positivo del medium supplementato usato per la preparazione dei 
poliplessi sulla vitalità cellulare ed è stata sottolineata l’importanza dello stato 
fisiologico delle cellule per poter ottenere buoni risultati di trasfezione e 
produzione. L’effetto da densità cellulare (cell density effect) è stato incontrato 
quando sono stati svolti esperimenti di trasfezione con concentrazione della coltura, 
benché, finora questo effetto sia stato descritto solamente in colture di baculovirus, 
tale effetto è stato evitato adattando un metodo di trasfezione alternativo. Lo studio 
della fase del ciclo cellulare ha posto in relazione una particolare fase del ciclo con 
la trasfezione, rivelando che cellule che si trovano nella fase G2/M sono più 
recettive alla trasfezione. Questi ultimi studi hanno evidenziato un forte effetto sulla 
trasfezione e sulla produzione del ricambio del medium precedente alla trasfezione, 
al riguardo del quale saranno necessari ulteriori approfondimenti. 
 
In chiusura vengono proposti esperimenti per risolvere i dubbi evidenziati dagli 
studi effettuati. Si propone nel dettaglio uno studio di microscopia confocale per 
ricavare i tempi precisi di trasfezione nel sistema utilizzato. Viene illustrato un 
metodo per eliminare l’effetto del cambio di medium negli studi sulle colture 
sincronizzate ed da ultimo metodi alternativi per lo studio dell’effetto della fase del 
ciclo cellulare. 
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The virus-like particles (VLPs) are very promising candidates for the development 
of new vaccines. The approaches for the large scale production of HIV-1 Gag VLPs 
have focused mainly on the expression system based on baculovirus. In this work, 
the HIV-1 Gag VLPs were produced using a protocol of transient expression, 
previously developed and optimized by the research group, in suspension culture of 
mammalian cells. The purpose of this work is to study the main variables in the 
process to understand what effect they can have on the transient transfection of the 
cells and on the same VLP production. 
 
To facilitate the quantification of VLPs , the Gag protein is expressed in fusion with 
the eGFP (enhanced Green Fluorescence Protein), thus generating fluorescent 
VLPs that can be quantified by fluorimetry. From previous studies performed by 
the research group, the great majority of the Gag-eGFP produced and present in the 
supernatant of the culture are properly assembled into VLPs, which show the 
provided morphology and dimensions, similar to those of immature viral particles 
of HIV-1. 
 
The culture medium used was previously optimized for the purpose, using the 
design of experiments (DoE). The result is a culture medium supplemented with 
non-animal derived components, which include recombinant proteins and synthetic 
lipids, capable of increasing cell growth and VLP production. The cells used are of 
a GMP-compliant line of human embryo kidney cells (Human Embryonic Kidney 
293, HEK293) that, in these conditions, grow up to a concentration of 4.8 million 
cells per ml, when grown in batch. 
 
The best performance of production is obtained when the cells are transfected 
during their exponential growth phase, with replacement of the culture medium 
with fresh medium at the time of transfection and using standard concentrations of 
plasmid DNA and polietilienimina (PEI). 
Using this method, on average, half of the cells in culture is positively transfected 
and produces about 2.7 billion VLPs per ml. The inherent problem of the method 
lies to the variability of transfection which also leads to a variability in the amount 
of VLP production. In this work, the results obtained maintain this trend. Thanks to 
a better understanding of the variables involved, it is possible to reduce the observed 
variability and increase productivity. 
 
It has been concluded that the transfection protocol is robust and not influenced by 
operational factors. Moreover, it was possible to define a positive effect of the 
supplemented medium used for the preparation of polyplexes on cell viability and 
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underline the importance of the physiological state of the cells in order to obtain 
good results of transfection and production. The cell density effect was met when 
transfection experiments were carried out with the concentration of the culture, 
although, so far, this effect has been described only in cultures of baculovirus , and, 
it was avoided by adapting an alternative transfection method. The study of the 
phase of the cell cycle has placed in connection a particular phase of the cycle with 
transfection, revealing that the cells that are located in the G2/M phase are more 
susceptible to transfection. These studies have shown a strong effect on transfection 
and production of the replacement of the medium prior to transfection, the matter 
of which will require further study. 
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5.1  TRADITIONAL VACCINES  AND THIRD GENERATION VACCINES  
 
A vaccine is a biological preparation that improves immunity to a particular disease; 
it typically contains an agent that resembles a disease-causing microorganism and 
that stimulates the body’s immune system to recognize such agent as foreign, 
destroy it and “remember” it, so that to easily recognize it in later encounters. 
 
The major types of vaccines licensed for use in humans can be divided into two 
main categories: traditional ones and modern ones (1). Traditional vaccines are 
classified in three kinds and there are many kinds of modern vaccines.  
Traditional vaccine kinds are: 
 
- Live attenuated vaccines: they consist in the same pathogen but with its 
virulent proprieties attenuated; the success of this approach depends on 
decoupling virulence from induction of protective immunity. Those were 
the firsts vaccines to be developed and work really well as they resemble 
the natural conditions and provide a lasting immunity. There are many 
examples of highly successful vaccines that have been developed like the 
current vaccine for tuberculosis. Often, multiple rounds of growth under 
conditions that weaken the organism such as in tissue culture or harsh 
physical conditions obtain the attenuated form of the pathogen. In these 
cases, the molecular basis of attenuation is unknown. New attenuated forms 
are likely to include the introduction of one or more specific mutations that 
interfere with synthesis of an amino acid or of a nucleic-acid essential for 
the growth of the organism (2). There are many disadvantages related with 
the use of live attenuated vaccines, as it multiplies in the patient and there 
is the possibility of reversion to virulence, due to a secondary mutation. This 
implies that live attenuated vaccines are suitable only for the vaccination of 
healthy adults (3). 
 
- Inactivated or killed organisms: these vaccines are safer in use as the living 
pathogen is inactivated in its virulence or killed. The inactivation is obtained 
through the action of chemicals, heat, radioactivity or antibodies, destroying 
the ability of the organism to replicate, making it impossible to retro-mutate. 
But, they tend to provide a shorter term immunity compared to live 
vaccines. For example, the Polio and the Hepatitis A vaccines are among 
this kind. 
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- Inactivated toxins: this kind of vaccine form the toxoid vaccines category 
and consists of compounds of the pathogen that cause illness rather than the 
pathogen itself. Because of their inability to replicate in vivo, these vaccines 
are generally less immunogenic than live vaccines and usually do not induce 
immune cellular response. One example for the development of inactivated 
toxins is tetanus, where the symptoms are caused by the neurotoxin 
produced by the bacteria and not by the bacteria itself. 
 
There have been many successes with traditional vaccines as it has been possible to 
improve immunity to Smallpox, Tuberculosis, Influenza, and Typhoid fever (only 
to name some of the most important ones), in fact, 90% of all recommended 
vaccines by the World Health Organization (WHO) belong to this category (4). 
However, an important limitation is safety: it is not always possible to identify 
sufficiently attenuated strains and there is an underlying risk of reversion to 
virulence, not to speak about the safety for who has to manipulate the vaccine. 
Moreover, traditional approaches have not been effective for many vaccine 
challenges, such as preventing or treating chronic infections and cancer, which may 
require induction of potent cellular immune responses. Some pathogens cannot be 
grown in vitro or, like in the case of Human Immunodeficiency Virus (HIV), some 
mutation rates are so high that make it impossible to develop a vaccine (5). 
 
With the term “new generation vaccines” or “modern vaccines” the following 
vaccine types are included: 
 
- Peptide vaccines: are based on chemical synthesis of a peptide that 
structurally resembles an antigen of the pathogen and which, when 
introduced into the host, the immune system recognizes as foreign antigens. 
These vaccines have the drawback that they are very quickly removed, 
therefore, the response that produce is much lower than conventional 
vaccines. On the other hand, they are more difficult to produce as the 
number of amino acids to form the peptide is the limiting step, with 50 being 
the maximum number of amino acids that can be bound in a chemical way. 
This type of vaccine is also valued as cancer treatment (6). 
 
- Live recombinant or genetically attenuated vaccines are the case in which 
the microorganism is genetically modified and may lead to total loss of 
pathogenicity of the organism (7). However, the immune response that 
occurs has to provide resistance, when the virulent pathogen will be present. 
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One of the major disadvantages of these vaccines is the probability to 
reverse. 
 
- DNA vaccines: this kind of vaccines is still in the experimental stages. They 
consist of a strand of DNA that codes for the antigens of the selected 
pathogen which will be introduced in the host cells, making them able to 
secrete such antigen and display it on their surface. In this manner, the host 
immune system will be stimulated to create a response. These vaccines 
would be relatively easy and inexpensive to design and produce. Naked-
DNA vaccines against influenza and herpes are being tested. 
 
- Recombinant vector vaccines are experimental vaccines that use an 
attenuated virus or bacterium to introduce part of the pathogen DNA into 
host cells. Thus, they work like DNA vaccines, but, a vector carries the 
genetic information. These vaccines closely mimic a natural infection, 
therefore are able to stimulate the immune system. By now, research focuses 
onto development of vaccines for HIV, rabies and measles. 
 
- Recombinant protein vaccines: this type of vaccine provides the advantage 
of not presenting a risk for the vaccinated nor for manipulators since it 
consists in the production by a particular cell type, either prokaryotic or 
eukaryotic, of recombinant proteins able to induce a protective immune 
response in the vaccinated. These proteins are generally pathogen antigens. 
The DNA encoding these antigens is introduced stably or transiently into 
cells, which synthesize the recombinant proteins. Later purification 
processes are performed, in which the vaccine is obtained. Within this type 
of vaccine, Virus Like Particles (VLPs) are found. These are particles that 
are structurally very similar to the wild-type virus, however, lack the 
necessary genetic information to replicate therein. 
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5.2  VIRUS-LIKE PARTICLES  
 
Virus-like particles are supra-molecular assemblages, usually icosahedral or rod-
shaped structures with diameters in range of 25-100 nm (8). They incorporate key 
immunogenic features of viruses like highly repetitive and ordered structures, 
particulate nature, ability to induce innate immunity for appropriate conditioning of 
adaptive immune responses, while lack genetic information with replicative 
capacity, just like recombinant subunits vaccines; thus represent an advanced 
vaccine technology platform (9) (10). 
 
Their recombinant nature means they can usually be manufactured economically in 
large-scale following current GMP. They display antigens in an ordered and 
repetitive way and thus induce rapid immune responses. Their particulate nature 
and dimensions means they are efficiently taken up by dendritic cells and 
transported to lymph-nodes. The ability of VLP polypeptide subunits to 
spontaneously assemble allows them to be disassembled and resembled in vitro, a 
process that permits stimulators to be packaged within their interiors. Nonetheless, 
antigens can be incorporated onto or into VLPs’ surface. Those are called VLP 
chimeras and have been extensively explored as vaccine-candidates since the mid- 
1980s (11): the introduced epitopes are presented in a repetitive and ordered 
fashion, at relatively high density and ideally with optimal accessibility and 
conformation, making them able to activate even B-cells (12). 
 
Vaccines in clinical development include those where the VLP itself represent the 
target epitope and those where the VLP is used to present a non-VLP derived 
epitope, i.e. an epitope that does not come from the proteins forming the VLP but 
from a third party. Two VLP-based antiviral vaccines have reached market: one 
against Hepatitis B Virus (HBV) and one against Human Papilloma Virus (HPV); 
and others are undergoing a number of clinical development programs such as VLP 
vaccines for influenza A, Norwalk virus, nicotine dependence, hypertension, 
Alzheimer’s disease (12). Several attempts have been made to induce an effective 
anti-HIV immune response (13) (10). Retroviral VLPs have also been successfully 
generated through the inoculation of Gag-Pol-expressing vectors in mice (14). 
 
5.2.1  HIV-1  PR55 G A G  VLPS  
 
The VLP expressed in this work is the HIV-1 Pr55Gag fused with the enhanced 
Green Fluorescent Protein (eGFP) to enable quantification of the final product (15). 
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The use of such VLPs has a number of advantages: the particle has the same size as 
the HIV and is easily identified by the immune system and the proteins that form 
the VLP can be engineered to exhibit at the surface of the particle one or more HIV 
antigens or other immunostimulatory molecules. HIV pseudovirion immunization 
has been shown to generate promising cell-mediated immune response in animal 
models and Pr55Gag-based VLPs have elicited strong cytotoxic T lymphocyte 
responses in mice (16). Intramuscular administration in macaques resulted in long-
lived cytotoxic T lymphocyte responses (17). Given such promising potential, it 
seems remarkable that no HIV pseudovirion approaches have advanced beyond 
early preclinical testing, maybe because of the complexities of production, envelope 
protein incorporation and stability, and purification. 
 
HIV is a lentivirus (slowly replicating retrovirus) that causes AIDS (acquired 
immunodeficiency syndrome), a condition in humans in which progressive failure 
of the immune system allows life-threatening opportunistic infections and cancers 
to thrive (18). HIV infects vital cells in the human immune system such as helper 
T cells, macrophages, and dendritic cells (5) leading to low levels of CD4+ T cells 
meaning loss of cell-mediated immunity (19). The HIV does not consist only of the 
Gag protein as its fundamental genes are gag, pol and env, which code for structural 
as well as enzymatic proteins, but, besides gag genes, these are not used for the 
expression of VLPs. The pol gene encodes for the virus polymerase and the env 
gene encodes for the envelope protein (Env, gp160), which is processed by the 
cellular protease to produce the membrane lipoprotein gp120 (SU), able to 
recognize and bind to the CD4 receptors. Apart from these, HIV also encodes 
proteins that have certain regulatory and auxiliary functions. It comprises two key 
regulatory elements: Tat and Rev and some other accessory proteins such as Nef, 
Vpr, Vif and Vpu related with the entrance in the host cell and the replication 
enhancing. (20) 
 
B 
 
FIGURE 1–  (A)  STRUCTURE OF THE MATURE HIV-1. (B)  STRUCTURE OF THE PRODUCED VLP. 
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The HIV type I (HIV-1) gag (group specific antigen) gene encodes for the highly 
conserved structural polyprotein Pr55gag, which directs the viral assembly process 
and is present at about 5000 copies per virion (21). Accurate crystal structures of 
Gag1-278 (i.e., the fused MA and CAN domains) at 2.2 Å resolution and the free 
CAN133-278 domain at 1.9 Å resolution have been obtained (22). The Gag protein 
comprises the major structural proteins p17 matrix (MA), p24 capsid (CA), p7 
nucleocapsid (NC) and p6 linker (LI), that are processed by the viral protease as 
virions bud from the host cell, thereby releasing discrete new proteins, as the small 
spacers peptides p2 and p1, required for maturation (23). 
 
FIGURE 2  - (A) CARTOON REPRESENTATION OF THE GAG1 -278  MA DOMAIN WITH SECONDARY STRUCTURES 
LABELED AND DISORDERED RESIDUES SHOWN AS DASHED LINES. (B) SAME AS (A) BUT FOR THE GAG1 -278  
CAN  133 -278  DOMAIN (22) 
The N-terminal MA domain confers membrane-binding activity to Gag, and the 
MA protein remains associated with the viral membrane after processing. 
Membrane binding is bipartite, with electrostatic interactions made by positively 
charged MA side chains and hydrophobic interactions provided by the insertion of 
MA’s N-terminal myristate moiety into the lipid bilayer (24). 
 
The CA region immediately follows MA in the HIV-1 Gag polyprotein and is 
comprised of two domains (25). The N-terminal domain mediates hexamer 
formation in the viral capsid, and the C-terminal domain mediates CA association 
of adjacent CA hexamers in the core (26). The extended Gag molecules adopt a 
radial distribution in the spherical immature particle, and the CA layer is located 
~100 Å from the membrane (27). During the subsequent process of maturation, 
~1000-1500 CA protein molecules rearrange to form the distinctive conical capsid 
of infectious virions. 
 
The p7 (NC) domain has the role to encapsulate and protect viral RNA and is 
important for efficient targeting and binding Gag to the plasma membrane (28) (29). 
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The role of RNA in virion assembly is so vital that 
HIV recruits other cellular RNAs if viral RNA is not 
available (30). (22) 
 
When the gag gene is expressed in appropriate cells, 
the Gag polyprotein is synthesized in the cytoplasm 
and then is targeted to the plasma membrane, where 
it acquires a lipid envelope and buds in form of VLP. 
During the cytosolic transport, it forms assembly 
intermediates, recruits single-strand RNA and 
aggregates at the inner face of plasma membrane as 
dense patches (10). 
 
Depending on the specific target of the VLP vaccine, different expression systems 
should be employed for expression of the required subunits: bacteria, yeast, plant 
cells, insect cells and mammalian cells can be used with pros and cons related (31). 
In fact, considerations such as appropriate protein glycosylation, correct folding and 
assembly favored mammalian cells as expression system, although they are more 
expensive (32). 
Bacteria are a wild used expression system in which the production is easy and the 
cost is low. Even the scaling process in easy, but bacteria are unable to introduce 
post-transcriptional modifications. The efficiency of the expression of viral 
components is variable and, usually, VLPs do no assemble if this system is used. 
The yeast expression system is similar to the bacterial expression system, with the 
pro that it is a eukaryotic system. Post-transcriptional modification are introduced 
but not with the same path as in mammalian cells. The main problem in the VLPs 
production is that, when produced, they are of low consistency and are separated 
from the cell cytoplasm into spheroplasts; the disruption of the cellular wall will be 
needed as well. 
Insect cells are a well studied expression system, the production cost is 
intermediate, scalability is easy and post-transcriptional modification are quite 
similar to mammalian cells. Producing VLPs in this system is hard, due to the use 
of baculovirus in this expression system, which has to be removed during 
downstream process (33). Moreover, the incorporation of insect proteins or 
baculovirus-derived proteins in the lipid envelope of HIV-1 Gag VLPs is known to 
provoke a strong immune response that can potentially mask the response against 
the desired envelope antigen (10) (33). 
If a mammalian cell is used as expression system, the production system will be 
very similar to the native pathogen-host cell, post-transcriptional modification will 
FIGURE 3  –  TEM  IMAGE OF  
ULTRATHIN SECTION SHOWING 
VLP BUDDING FROM HEK293 
PRODUCER CELL. BAR 100µM (60) 
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be adequate and the final product will have a good quality. Although, their cost is 
high and the productivity is low. (34) 
 
5.3  HUMAN EMBRYONIC K IDNEY CELL LINE  
 
The expression system used in this work is a mammalian cell line, precisely the 
Human Embryonic Kidney cell line HEK293 SF-3F6. HEK293 cells are easy to 
grow and transfect, they are an excellent cell line to use in transfection experiments, 
or to produce recombinant DNA or gene products. The introduction of plasmid 
vectors such as those under the control of the CMV promoter very effectively 
hijacked the HEK cell’s synthetic protein machinery and forced the translation of 
gene products artificially incorporated into the plasmid (35). This has made them a 
popular research tool in cell biology studies, and an ideal cell line for therapeutic 
protein and virus production by the biotechnology industry. 
 
HEK293 cells were generated over 40 years 
ago by transformation of human embryonic 
kidney cell culture with sheared fragments of 
adenovirus type 5 (Ad5) DNA in the 
laboratory of Alex Van Der Eb in Leiden, 
Holland. The original culture was created by 
Van Der Eb using some kidney cells from an 
aborted fetus and were transformed by 
Graham (36) as he was working on DNA-Calcium Phosphate transfection of rat 
embryo and kidney cells since a couple of years (37), hence, the number 293 is used 
because that was his 293rd transfection experiment. Since many kinds of cell belong 
to the kidney tissue, it is impossible to know exactly from which the HEK293 cell 
line comes from, but, their genomic characteristics have been studied (38). The 
transformation permanently incorporated around 4.5 kb of the left arm of the Ad5 
genome into chromosome 19 of the host genome; such modification was 
subsequently used for the generation of transcription incompetent human 
adenoviral vectors. This cell line presents a mode of 64 chromosomes per cell (i.e. 
two or more copies of each chromosome), including three copies of the X 
chromosome and four of the chromosomes 17 and 22. 
 
When cultivated, these cells have to be grown in adhesion until they are ~ 70% 
confluent; after some passages in adhesion, they can be adapted for growth in 
suspension. In order to make them adhere, incubation at 37 °C is necessary, 
A       B 
FIGURE 4  –  HEK293 OPTICAL MICROSCOPE 
IMAGE . (A)  CULTURE IN ADHESION , ALMOST 
CONFLUENT. (B)  CULTURE IN SUSPENSION . 
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meaning also that they can be transported, without any mechanical damage, in 
suspension. 
 
The cell line used in this work grows in suspension in the FreeStyle culture medium 
optimized with the addition of animal-free supplements, that permits to reach high 
cell densities (39). Cell morphology is shown in Figure 4: suspension cells have a 
round shape and do not interact physically with each others. 
 
5.4  TRANSIENT TRANSFECTIO N  
 
Transfection is the process of deliberately introducing foreign nucleic acids, such 
as supercoiled plasmid DNA, into eukaryotic cells to get them expressed. There are 
different methods to obtain transfection: some rely on physical treatment, such as 
electroporation, others on chemical materials, such as the use of calcium phosphate 
or cationic polymers, like polyethylenimine (PEI), or biological particles, such as 
viruses as carriers. Transfection can result in the generation of a stable line 
expressing the introduced trans-genes. Stable transfection in more difficult to obtain 
because the transfected DNA has to remain in cell genome and to be passed to the 
daughter cells through generations. Transient transfection is easier, compared to 
stable transfection, as the transgenic material is not integrated into the nuclear 
genome, although it enters the cell nucleus, allowing expression of the transgene, 
which will be diluted through mitosis or degraded. This is why stable transfection 
is usually preferred by industries, as they want a product to be expresses in a stable 
manner without warring about the production rates. Nonetheless, transient 
transfection is a suitable technique for academics or early expression studies that 
could be done before and to test the feasibility of a stable line. In fact, this method 
is very flexible, as it is possible to generate different candidate products in a fast 
and easy way, in order to test them for the searched characteristics. 
 
The technique used in this work for the production of VLPs is the transient 
transfection mediated by PEI. Since its introduction in 1995, PEI has become one 
of the most efficient non-viral gene-transfection agent. It is a cost-effective and 
efficient method (21) based on the use of cationic polymers. Cationic polymers have 
a positive charge and thus are able to complex DNA, which has a negative charge, 
and to cross the cellular membrane, which has a global negative charge too and an 
inner hydro-carbonic appearance, even reaching the nucleus through diffusion.  
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Despite the high efficiency of the method there is a high variability in the positive 
cell transfection percentage and the recombinant protein production. 
 
Many points of the methods have been widely investigated to find ways to reduce 
its variability. Now it is known that branched and linear PEI/DNA complexes differ 
in their ability to transfect cells. The greater efficiency of linear PEI might be due 
to an inherent kinetic instability under salt solution (40). The structure PEI/DNA 
complexes has been quantitatively analyzed as well. 
 
The role of the cellular state has been studied as well. It has been shown that beyond 
the mid-log phase point of the growth of cell that have to be transfected, VLP 
production is limited by a significant loss in transfection efficiency. These 
observations are also in agreement with those reported by Carpentier et al. (41) who 
concluded that successful transgene expression is more likely to depend on a 
“cellular competent state” than on the quantity of plasmid DNA delivered per cell. 
In this sense, Brunner and collaborators have indicated that transfection efficiency 
is strongly dependent on the cell cycle stage at the time of transfection, with cells 
in the G2/M phase giving greater levels of transfection than G1 cells (42). The 
authors have hypothesized that transport of DNA into the nucleus is a very 
inefficient process and that transfection of cells shortly before their next cell 
division (close to M phase) is facilitated by nuclear membrane breakdown. In 
support of these studies, Tait et al. (43) have shown that both transfection efficiency 
and protein expression can be enhanced by arresting cells in G2/M phase using 
Nocodazole. 
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5.5  CELL CYCLE  
 
Through the cell division process, known as cytokinesis, a mother cell divides into 
two daughter cells, transmitting them its whole genetic information in equal 
quantity. Each new cell division corresponds to a new cell cycle. Cells going 
through the actual division process are in the mitosis (M) phase and non-dividing 
cells are in interphase. Interphase may last for different periods of time (hours, days, 
weeks, or longer) depending on the cell type and it is divided into three phases: gap 
one (G1), synthesis (S) and gap two (G2). 
 
 
FIGURE 5  - CELL CYCLE SCHEME 
To provide a complete set of genetic material for each of its two daughter cells, the 
genetic information of the mother cell has to be duplicated, resulting in a cell with 
twice the normal amount of DNA. This duplication of the genome is performed 
during the S phase. Afterwards, mitosis occurs and the two daughter cells each have 
a full copy of the DNA. The S phase and mitosis are separated by the G2 phase 
where a checkpoint for completed DNA synthesis occurs. Mitosis and the S phase 
are separated by the G1 phase in which a checkpoint for DNA damage occurs. Cells 
can reversibly enter a resting phase (G0) during G1 phase, if environmental 
conditions are not sufficient for growth and division. 
 
5.5.1  STUDY OF THE C ELL C YC LE 
 
Different approaches exist to study the cell cycle such as monitoring the cell 
concentration with time as well as the use of specific stains, combined with flow 
cytometry; this provides determination of percentage of cells present in the different 
phases of the cell cycle. 
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A normal cell culture appear asynchronous, as each cell proceeds independently 
through cell cycle, so it results that the whole culture is randomly distributed 
throughout the different cell cycle phases. In order to study the effect of a specific 
cell cycle phase it is necessary to have a synchronized culture, or at least a culture 
enriched with a good amount of cells in the same cycle phase.  
 
5.5.1.1 CELL S YNCHRONIZATION  
 
Many different approaches have been published to achieve cell synchronization 
among a given population in culture. The two main approaches are by using a drug 
that inhibits the progression in the cell cycle and by physiological means such as 
contact inhibition or nutrient deprivation. Reversible inhibitors of cellular DNA 
synthesis are useful tools for synchronization as cycling resumes upon drug 
removal. However, when an asynchronous cell population is treated, only cells 
reaching the point in the cell cycle inhibited by the drug will get affected by the 
synchronization agent and accumulate at that point. 
 
Synchronization over more than one or two cell cycles is difficult to achieve due to 
the fact that as soon as the synchronization factor is removed, each cell will again 
cycle on an individual basis, independently of the state of the cells surrounding it. 
The cause of de-synchronization is not understood but has been attributed to 
intracellular fluctuations in the number of key molecules necessary for the initiation 
of DNA synthesis (44). 
 
CHEMIC AL SYNC HRONIZ AT ION 
 
In this work, two chemical reagents have been used with the aim to obtain two 
different synchronized cell cultures: Hydroxyurea and Nocodazole. 
 
Hydroxyurea: it is an anti-neoplastic drug used against chronic myeloproliferative 
syndrome, besides being used for pain in sickle cell disease. It also has antiretroviral 
capabilities. Advantage was token from its propriety as DNA replication inhibitor 
FIGURE 6  - HYDROXYUREA 
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since it inhibits conversion of ribonucleotides to deoxyribonucleotides (45). The 
effect is cell line dependent: HEK293 resulted blocked in G1 phase. 
 
Nocodazole: it is an anti-neoplastic agent that arrests the cell cycle interfering with 
microtubule polymerization thus blocking cells in G2 or M cell cycle phase. Cells 
are able to enter mitosis but are unable to form the spindle apparatus as microtubules 
cannot be polymerized, thus activating the mitosis checkpoint (46). Long exposure 
to Nocodazole can lead to apoptosis. Furthermore, as organizing the perinuclear 
Golgi structure is microtubule polymerization dependent, Golgi structure is 
inhibited by Nocodazole too. Blocking cells in G2-M phase could lead to high 
transfection percentages, due to lack of cellular membrane; however, Nocodazole 
does not synchronize cells, as, when removed, a synchronized culture is not 
obtained (47). 
 
 
FIGURE 7  - NOCODAZOLE 
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This work aims to optimize the production of Gag-eGFP VLPs in HEK293 cells 
through a better understanding of some important variables that have to be taken 
into account during the process. 
 
The independent study of different variables provides ways to understand better the 
mechanisms implied in the formation of the PEI/DNA polyplexes used for the 
transient transfection of cells and the process of PEI mediated transient transfection 
itself. 
 
Various methods exist to transfect mammalian cells in culture. It is generally 
accepted that individual methods have to be optimized for each of the cell lines or 
cell types used. Despite the fact that PEI transfection is widely used, many questions 
about its mode of action remain. Repetitive transfections in apparently identical 
conditions may results in significant day-to-day variation efficiency, despite the use 
of optimized protocols. Parameters as cell density, cell physiological state, cell 
stress state, cell cycle phase but also as modes of preparation of the PEI/DNA 
polyplexes play an important role in efficient transfer of plasmid DNA into nuclei 
of host cells. 
 
A better understanding of the PEI transfection is expected to result in a more 
efficient ratio between plasmid DNA input and recombinant protein output. 
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7.1  PLASMID PREPARATION  
 
The pGag-eGFP plasmid used for generation of fluorescent VLPs was kindly 
provided by Dr. Julia Blanco at Fundació IRSI Caixa, Hospital Germans Trias i 
Pujol in Badalona, Spain. This plasmid codes for a Rev-independent HIV-1 Gag 
protein fused in frame to the enhanced GFP (48). The plasmid from the NIH AIDS 
Reagent Program (Cat 11468) was constructed by cloning the Gag sequence from 
pCMV55M1-10 (49) into the pEGFP-N1 plasmid (Clontech, Palo Alto, CA, USA). 
 
The plasmid was amplified in competent Escherichia Coli DH5α strain stored in 
100 µl samples at -80 °C, transfected by thermal shock and grown in LB medium 
(Conda, Madrid, Spain) supplemented with Kanamicin (10 µg/ml, Sigma, Saint 
Louis, MO, USA). Plasmid purification was carried out using the Endofree Plasmid 
Maxi kit (Qiagen, Hilden, Germany), according to manufacturer’s instructions, as 
previously described (50). 
 
 
FIGURE 8  –  PGAG-EGFP  DIAGRAM AND AGAROSE GEL IN WHICH THE PLASMID WAS RUN AFTER SEVERAL 
EN ZYME DIGESTIONS.  RUN 1: MOLECULAR WEIGHT MARKER; 2: CONCENTRATED PLASMID; 3: PLASMID  
DIGESTION WITH ECO-NOT;  4: PLASMID DIGESTION WITH BAM-KPN. 
DNA concentration and purity were assessed using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). DNA integrity was 
evaluated by agarose gel electrophoresis and its identity confirmed by restriction 
mapping. Purified plasmids were typically in supercoiled form, free of RNA 
contamination and showed an A260/280 ratio of approximately 1.85. They were 
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diluted in mQ sterile water to achieve a final concentration of 100 ng/µl in the stock 
solution. 
 
7.2  CELL LINE  
 
The cell line used for VLP production is the HEK 293SF-3F6, kindly provided by 
Dr. Amine Kamen from the Biotechnology Research Institute (BRI), National 
Research Council (NRC) in Montreal, Canada. It was derived from a cGMP master 
cell bank that is available for manufacturing of clinical material. These cells were 
adapted to grow in suspension and serum-free conditions. Cells were cultured in 
FreeStyle 293 medium (Invitrogen, Carlsbad, CA, USA) optimized with the 
addition of non-animal derived components (39). The supplements used are r-
insulin and r-transferrin from Merk Millipore (Kankakee, IL, USA) and an in-house 
developed animal component free lipid mix composed of synthetic cholesterol 
(SyntheChol®, Sigma-Aldrich, Steinheim, Germany), fatty acids (F7050, SAFC 
Biosciences), tocopherol (T1 157, Sigma) and emulsifying agents (PS80, Sigma), 
whose optimal concentrations were defined by DoE (39). Cells were routinely 
maintained in 125 ml disposable polycarbonate Erlenmeyer flasks (Corning, 
Steuben, New York, USA) shaken at 110 rpm using an orbital shaker (Stuart, Stone, 
UK) containing a working volume of 20 ml. HEK 293 cells were maintained at a 
concentration between 0.3 and 2×106 cells/ml and viability usually between 85 and 
95% in a humidified incubator at 37°C and 5% CO2 in air. Cell density and viability 
were determined using a haemocytometer chamber (Neubauer) under an inverted 
phase contrast microscope (Zeiss, Germany) and trypan blue exclusion dye (Sigma, 
Steinheim, Germany) at a final concentration of 2% v/v. The average density of 
cells in the diluted sample for cell density and viability determination was around 
25 cells per field. Equation [1] was used for cell density determination both of living 
and death, while equation [2] was used for viability assessment; n factors are the 
number of cells counted per field, discarding the most and the less populated four 
fields among the total eight. 
 
𝐶𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (
106𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
) =  
𝑛1+𝑛2+𝑛3+𝑛4
2
∗
𝑓𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
 [1] 
 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝐿𝑖𝑣𝑖𝑛𝑔 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐿𝑖𝑣𝑖𝑛𝑔 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛+𝐷𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
∗ 100 [2] 
 
Characterization of the exponential growth curve was done determining the kinetic 
parameters of the phase. The specific growth rate (µmax) is constant and maximum 
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[4] 
[3] 
in this phase and describes the duplication rate; it can be calculated through 
regression of the living cells concentration. The doubling time was calculated 
through the equation [3]: 
 
𝑡𝑑(ℎ) =
ln (2)
µ𝑚𝑎𝑥
 
 
7.3  PRODUCTION AND HARVES T OF GAG-EGFP  VLPS  
 
VLPs were produced by transient transfection of HEK 293 cells with Gag-eGFP 
plasmid DNA using 25 kDa linear PEI (PolySciences, Warrington, PA) as 
transfection reagent. Cells were typically transfected at 2×106 cells/ml (unless 
stated otherwise). The final DNA concentration was 1 µg/ml and the PEI:DNA 
mass ratio used for transfection was 2:1. DNA-PEI polyplexes were prepared in a 
volume of culture medium that corresponded to 10% of the final volume to be 
transfected. PEI was added to plasmid DNA diluted in culture medium. The mixture 
was vigorously vortexed three times and incubated at room temperature for 15 min 
before being added to the cell culture. Cell suspensions were harvested at the 
indicated time post-transfection. Cells were centrifuged at 1000×g for 5 min to 
separate cells and cell debris from cell culture supernatants containing VLPs. 
 
7.4  QUANTIFICATION OF GAG-EGFP  VLPS BY 
SPECTROFLUOROMETRY  
 
Green fluorescence intensity in Gag-eGFP VLPs samples was measured by 
spectrofluorometry using a Cary Eclipse Fluorescence Spectrophotometer (Agilent 
Technologies, Santa Clara, CA, USA). The instrument parameters were set as 
follows: λex= 488 nm (slit 5 nm), λem = 510 nm (slit 10 nm). Readings were carried 
out at room temperature. Relative fluorescence units values (RFU) were calculated 
by subtracting fluorescence intensity (FU) of negative control samples that were 
systematically included in every assay (usually, supernatant from untransfected 
cells or culture media) from the fluorescence given by the sample. RFU values can 
be converted to Gag-eGFP VLPs concentration values using equation [4], as 
previously described by the research group (15). There is a linear correlation 
between fluorescence intensity and p24 values determined using the INNOTEST 
ELISA HIV antigen mAb (Innogenetics NV, Gent, Belgium). 
 
𝐺𝑎𝑔 − 𝑒𝐺𝐹𝑃 [
𝑛𝑔
𝑚𝑙
] = (3.6126 × 𝑅𝐹𝑈 − 14.935) × 36 
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Where Gag-eGFP is the estimated concentration of polyprotein and RFU is the 
measured eGFP fluorescence intensity of the samples. The first term is the 
correlation equation between fluorescence values and p24 concentrations 
determined by ELISA (Enzime-Lynked ImmunoSorbent Assay) and 36 is a 
correction factor that takes into account the difference in molecular weight between 
p24 and Gag-eGFP and an underestimation arising from using the p24 ELISA to 
estimate p55 Gag concentrations. 
 
7.5  QUANTIFICATION OF TRA NSFECTED CELLS  
 
The percentage of positively transfected cells at the indicated time post-transfection 
was quantified by flow cytometry. Cells were fixed in order to enable later 
subsequent analysis. A 500 µl sample was harvested and centrifuged at 300×g for 
5 min and consequently fixed through resuspension in formaldehyde (2% in PBS) 
for 10 min; afterwards the sample was centrifuged at 500×g to remove the fixation 
agent and resuspended in PBS. Fixed cells were analyzed in a FACSCanto Flow 
Cytometer (BDBiociencies, San Jose, CA) before five days after fixation. 
 
 
FIGURE 9  –  TYPICAL TRANSFECTION RESULTS. GRAPH A SHOWS THE TYPICAL ANALYSIS RESULT OF A 
CONTROL (I.E. NOT TRANSFECTED) CULTURE. GRAPH B SHOWS THE TYPICAL ANALYSIS RESULT OF A 
TRANSFECTED CULTURE; TWO POPULATIONS ARE VISIBLE: BLUE ONE (NOT TRANSFECTED CELLS) AND 
GREEN ONE (POSITIVELY TRANSFECTED CELLS). 
 
 
 
A B 
A B 
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7.6  DETERMINATION OF CELL  CYCLE PHASE  
 
At the indicated time-point a 1 ml sample was taken from the cell culture and fixed 
for cell cycle analysis. 
 
7.6.1  CELL FIXATION AND STA INING  
 
The sample was centrifuged at 200×g for 6 min to harvest cells, rinsed and re-
suspended in 500 µl PBS, than fixed with 4.5 ml cold 70% v/v ethanol for a 
minimum of 2 h at -20 °C to fix cells. Subsequently, fixed cells were centrifuged at 
200×g for 5 min, rinsed and stained with 1 ml of staining solution for at least 1 h at 
room temperature prior data acquisition. The staining solution consist of 20 µl of 
Propidium Iodide 1 mg/ml (PI) (Sigma) solution, 20 µl RNase DNase-free 10 
mg/ml solution and 1 µl 0.1% v/v TritonX-100 solution in PBS per each ml of final 
volume. 
 
PI is an intercalating agent with excitation wavelength at 535 nm and emission at 
617 nm, when it is bound to nucleic acids; nucleic acids bounding also enhances 
around 30-fold its fluorescence. Thus, PI does not interfere with the excitation 
wavelength of the eGFP. PI has no sequence preference but binds to RNA too, thus 
necessitating a previous sample treatment with RNases (51). 
 
7.6.2  FLOW C YTOMETRY ANALYS IS 
 
The DNA content of a cell doubles during S phase and maintains its maximum 
quantity during G2 and M cell cycle phase before cytokinesis. It is possible, using 
specific fluorescent DNA, stains such as PI to quantify the relative amount of DNA 
in each cell of a population using flow cytometry. The result is a cell cycle profile 
of the analyzed population, a histogram reflecting the distribution of cells according 
to their DNA content. Cells with double DNA amount will have twice the 
fluorescent signal than cells with normal DNA quantity. Cells actively duplicating 
their DNA will have a fluorescent signal that falls in-between. 
 
Forward scatter, side scatter and UV-fluorescence (FL4) were acquired with a 
FACSCalibur Flow Cytometer (BD, San Jose, CA, USA) for each sample. Cell 
cycle analysis was performed on the acquisition of minimum 20’000 events in order 
to have well defined profiles. Determination of the percentage of cells in the 
different phases of the cell cycle was done through software analysis (Mod Fit LT, 
MA TERIALS A ND METHODS 
32 
Variety Software House, Tropsham, ME, USA) when well distinguishable G0/G1 
and G2/M peaks were present. For blocked or synchronized populations, when 
G0/G1 or G2/M peaks were not present (or not significantly enough to be 
recognized as such by software analysis), gating of regions of interest was 
performed to calculate the percentage of cells in the different phases. Regions gated 
manually were compared with software analysis for well-defined profiles to ensure 
that the estimation was correct. 
 
 
FIGURE 10 – TYPICAL RESULT OF A CELL CYCLE ANALYSIS. Y-AXIS INDICATES THE NUMBER OF CELLS WITH SUCH 
FLUORESCENCE, X-AXIS IS DIVIDED INTO CHANNELS CORRESPONDING TO AN IDENTICAL AMOUNT OF DETECTION 
WINDOW FOR INCREASING FLUORESCENCE INTENSITY. RED PEAK AT CHANNEL 46.81 INDICATES G0/G1 PHASE CELLS; 
RED PEAK AT CHANNEL 92.41 INDICATES G2/M PHASE CELLS; GREY AREA INDICATES S PHASE CELLS. 
 
7.7  MTT  ASSAY  
 
MTT assay is a colorimetric assay for measuring activity of cellular enzymes which 
reduce the tetrazolium dye (MTT) to its insoluble form (formazan), giving a purple 
sample. In cell biology, this test is used to assess cell viability. The MTT is reduced 
to formazan in the presence of living cells. 
 
In this work, the MTT assay was used for toxicity testing. In a 96-well plate were 
cultivated 100 µl HEK293 at the concentration of 0.5×106 cells/ml together with 10 
µl of different concentrations of the compound under toxicity testing. The plate was 
grown under standard HEK293 cell culture conditions. After three days, 20 µl of 
MTT reagent were added to each well and the plate was again incubated for one 
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hour at 37 °C with agitation of 110 rpm. The day of the test was conducted using a 
12 wells as calibration line. In each of these 12 wells, 100 µl of HEK293 cells at 
various concentrations, ranging from 0 up to a maximum concentration 2×106 
cells/ml were placed. Such curve was performed in duplicate. 
 
Absorbance was measured in a spectrophotometer at a wavelength of 490 nm. 
Using data obtained from the calibration curve, it was possible to extrapolate the 
absorbance values at the cell concentration, which indicates the toxicity of the 
various compounds tested. 
 
7.8  CELL CYCLE CHEMICAL B LOCKING AND CELL 
SYNCHRONIZATION  
 
The cell cycle phase profile of a normal, i.e. non-synchronized, inoculum was 
followed. To draw this profile the growth in supplemented FreeStyle medium of an 
inoculum of 20 ml of cells at the concentration of 0.3×106 cells/ml was followed 
for eight days and cell cycle analysis done every 24 h. Exact percentages highly 
depend on several variables such as cell state, exact time of analysis and more. In 
order to be used as control, the cell cycle phase profile of cells at the concentration 
of 2×106 cells/ml was also followed for 24 h and analyzed every hour.  
 
Cell cycle blocking was performed using two different reagents in separated 
experiments to control that no side effects arose from the use of the drug. 
Nocodazole was used to arrest the cells in the prometaphase and thus enrich the 
culture with G2/M phase cells, as it is known that Nocodazole-treated cells arrest 
with a G2- or M-phase DNA content when analyzed by flow cytometry.  
Hydroxyurea was used to arrest the cells in the G0/G1 phase. Drug blocking effect 
was assessed by following cell cycle phase kinetics. 
 
7.8.1  CELL C ULTURE C HEMIC AL  SYNC HRONIZ ATION  
 
Drug removal was done by medium exchange and flask change: the whole culture 
volume was centrifuged at 200×g for 6 min to harvest cells which were then 
immediately and gently resuspended in the same volume of fresh pre-heated 
medium in a new Erlenmeyer flask. 
Cell cycle phase deregulation kinetics were followed by cell cycle analysis, cell 
concentration and viability. 
 
 34 
 
 35 
 
 
 
 
 
 
 
 
 
8 RESULTS AND DISCUSSION  
 
 36 
RESULTS A ND DISCUSSION  
37 
8.1  GROWTH PROFILE  
 
The growth of the HEK293 cell line in supplemented FreeStyle medium has been 
followed starting with an inoculum of 0.3×106 cells/ml. Cell concentration and 
viability have been assessed every twenty-four hours (Figure 11). 
 
 
FIGURE 11  - HEK293  GROWTH CURVE IN SUPPLEMENTED FREESTYLE CULTURE MEDIUM.  
The cell inoculum is adequate as there is no lag phase and cells directly enter log 
phase; exponential growth lasts four days, consequently cells enter stationary phase 
and, at seventh day, start to die. The culture grows to a maximum concentration of 
4.80×106 cells/ml with over 85% viability and shows an average doubling time of 
33.2 h, the calculated maximum growth rate (µmax) is 0.021 h
-1; these data are in 
agreement with previous work (39). 
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8.2  TRANSFECTION PROTOCOL  STRENGTH TES TING  
 
The main problem of the transient transfection is its efficiency variability, which 
makes industries discard this technique when they want to prepare a product for the 
market. In the results obtained in this work, such variability could also be observed, 
as it can be noticed in Figure 12. Each replicate was performed by following always 
the standard protocol, but, even so, variability on positively transfected cells and 
quantity of VLPs produced was high. Usually, the average transfection percentage 
is 45% 48 hpt and 55% 72 hpt, while the average VLPs production is quantified 
around 22 RFU 48 hpt and 35 RFU 72 hpt. 
 
FIGURE 12  –  POSITIVELY TRANSFECTED CELLS PERCENTAGES AND THE RELATIVE FLUORESCENCE UNITS 
OF THE CULTURE SUPERNATANTS 48  HPT IN THIRTY-THREE INDEPENDENT EXPERIMENTS.  
In order to reduce this variability a wide range of variables in the transfection 
protocol was taken into account; after compiling a list of those convided more 
relevant, a large number of experiments was done to evaluate each variable effect 
independently. Each experiment has been done in triplicate to evaluate standard 
deviation and repeated more times to assess repeatability. 
 
The tested variables were the following: 
 
- Variables affecting the polyplexes formation: 
 
o Supplemented vs. non-supplemented FreeStyle culture medium as 
solvent for the DNA and PEI mixture; 
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o Pre-heated vs. not pre-heated culture medium as solvent for the 
DNA and PEI mixture; 
o Vortexed vs. not-vortexed mixture for the preparation of 
polyplexes; 
 
- Variables affecting the transfection procedure: 
 
o Age of used flasks; 
o Cell stress due to medium exchange; 
 
- Not-depending on the protocol variables: 
 
o Cell passage at transfection time-point; 
o Cell concentration at transfection time-point; 
o Cell cycle phase at transfection time-point. 
 
For each, the routine transfection procedure was strictly followed a part of the tested 
variable; cell growth, viability and positively transfected cells percentage was 
quantified 24, 48 and 72 hpt, as well as VLPs production; p-values were calculated 
with the null hypothesis that the results are significantly different. 
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8.2.1  SUPPLEMENTED VS .  NON-SUPPLEMENTED FREESTYLE C ULTURE 
MEDIUM AS SOLVENT FO R THE DNA  AND PEI  MIXTURE  
 
Supplemented FreeStyle medium was used as solvent for the DNA and PEI 
mixture to analyze if it has any effect over transfection and VLP production. As 
control, the solvent used to prepare the mixture was non-supplemented FreeStyle 
medium. Results are shown  
Figure 13. 
 
There is no significant difference in transfection efficiency and VLP production 
between using one or the other medium, although it could be sad that cells are 
positively affected by a second addition of a 10% in culture volume of fresh 
medium, leading to a higher viability of cells in the off 72 hours. Nonetheless, the 
supplemented components added to the FreeStyle medium do not interact with 
DNA and PEI prejudicing polyplexes formation. Based on these data, supplemented 
FreeStyle medium was from now on used as solvent for the preparation of 
polyplexes. 
  
 
 
FIGURE 13  –  SUPPLEMENTED FREESTYLE CULTURE MEDIU M AS SOLVENT FOR THE DNA AND PEI  MIXTURE 
RESULTS. (A)  CELL CONCENTRATION AND VIABILITY; (B)  TRANSFECTION PERCENTAGES; (C)  VLP   
PRODUCTION . 
  
B A 
C 
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8.2.2  PRE-HEATED VS .  NOT PRE-HEATED C ULTURE MEDIU M AS S OLVENT FOR  
THE DNA  AND PEI  MIXTURE  
 
Cell growth, transfection efficiency and production were compared between cells 
transfected using a not-pre-heated solvent per mixture and a control mixture 
where the solvent was pre-heated.  Following the routine procedure, the solvent 
used to prepare the mixture has to be pre-heated at 37 °C (the same temperature as 
the cultivated cells) before the reagents addition. But, as it is stored at 4 °C, this 
could lead to loss of time and/or to inhomogeneous proper heating of the culture 
medium. Results are shown in  
Figure 14. 
  
The addition of such cold volume affects cells viability for the firsts hours post 
transfection but has no effect on the percentage of transfected cells and quantity of 
VLPs produced at the hours post transfection (hpt) of interest. 
 
 
 
FIGURE 14  – NOT PRE-HEATED SOLVENT FOR THE DNA AND PEI  MIXTURE RESULTS. (A)  CELL 
CONCENTRATION AND VIABILITY; (B) TR ANSFECTION PERCENTAGES; (C)  VLP PRODUCTION 
  
B A 
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8.2.3  VORTEXED VS .  NOT-VORTEXED MIXTURE FOR  THE PREPARATION OF 
POLYPLEXES  
 
One of the lasts steps in the mixture preparation is the vortexing step: the mixture 
has to be vortexed 10 sec to dissolve DNA and 3 times per 2 sec to solubilize PEI. 
Cell concentration and viability after transfection, positively transfection 
percentages and VLP production data of a cell culture transfected using a not-
vortexed mixture were compared with a control culture transfected using a vortexed 
mixture. The not-vortexed mixture was gently inverted one time and the control 
mixture was vortexed as stated by the standard protocol. Results are shown in  
Figure 15. 
 
Cells are transfected even in the not-vortexed case, meaning that the polyplexes are 
however able to form. Transfection percentages are comparable with the control at 
the indicated hpt. Cell concentration and viability are not affected by the vortexing 
step as these data are comparable between the not-vortexed case and the control.  
 
 
FIGURE 15  - NON-VORTEXED DNA AND PEI  MIXTURE RESULTS. (A)  CELL CONCENTRATION AND 
VIABILITY; (B) TRANSFECTION PERCENTAGES; (C)  VLP PRODUCTION .  
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8.2.4  AGE OF F LASKS  
 
The polycarbonate Erlenmeyer flasks used in this work are designed for single use, 
but, due to their expensive cost, they were re-used. The flasks are routinely cleaned 
at the end of an experiment, but the cleaning and sterilization procedure could in 
some way affect their integrity and thus affect the final results of the experiments. 
In fact, the cleaning and sterilization procedure includes 10 min sonication at room 
temperature while washing with 1 M sodium hydroxide, abundant water and mΡ 
water rinsing, and irradiation with gamma ray. Old flaks, i.e. flasks that have 
undergone a large number of cleaning and sterilization cycles, appear matter than 
new ones. 
 
In order to evaluate if the age of the flask used to culture cells may have some 
effect over cell growth, transfection and production, cells were re-suspended after 
medium exchange (and before transfection) in a completely new Erlenmeyer 
flask. Results were compared with a parallel experiment done using some visibly 
very opaque flasks. Results are shown in  
Figure 16. There is no considerable effect on cell growth post-transfection, 
transfection efficiency and VLPs production so, this variable has no influence. 
 
 
 
FIGURE 16  –  NEW FLASK AS CULTURE FLASK AFTER TRANSFECTION . (A)  CELL CONCENTRATION AND 
VIABILITY; (B) TRANSFECTION PERCENTAGES; (C)  VLPS PRODUCTION .  
  
B A 
C 
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8.2.5  CELL STRESS DUE TO ME DIUM EXC HANGE  
 
The procedure used for transfection states to exchange culture medium with fresh 
medium before transfecting, as this influences cells making them more active and 
permits to eliminate possible sub-products secreted by cells during their culture, 
that could interfere with transfection. As it involves a centrifugation step and some 
re-suspensions trough pipetting, it could also stress cells. To test if this variable has 
some effect, a cell culture was incubated four hours after medium exchange and 
before transfection, to let cells escape such “stress state”. 
 
Cell growth, transfection efficiency and VLP production were quantified 
comparing with a control experiment where cells were not subjected to the extra 
incubation time. Results are shown in  
Figure 17. No significant differences between the two conditions were observed, 
thus, this variable has no effect.  
 
  
 
FIGURE 17  – ADDITIONAL INCUBATION TIME RESULTS.. (A)  CELL CONCENTRATION AND VIABILITY; (B)  
TRANSFECTION PERCENTAGES; (C)  VLPS PRODUCTION . 
B A 
C 
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8.2.6  CELL PASSAGE AT TRANS FEC TION TIME-POINT  
 
For maintenance, every two or three days cells are reseeded at a final 
concentration of 0.3×106 cells/ml, resulting in a new passage. Cells available in 
the master cell stock are around passage 40 and can typically be maintained until 
passage 100. To know if cells react differently to transfection due to their passage, 
recently de-frozen cells (passage 47), mid-age cells (passage 77) and old cells 
(passage 97) were transfected. Results are shown in  
Figure 18. 
 
Thus, the passage number does not influence transfection, neither VLP production, 
but, as the technique has a toxic effect over cells, it is important not to use too old 
cells. Many cells are killed by transfection and those who survive decrease their 
growth rate, as VLP production requires a strong metabolic effort, even due to the 
CMV promoter. This is why the use of use of old cells must be avoided. 
 
 
 
FIGURE 18  - CELL P ASSAGE EFFECT RESULTS. (A)  CELL CONCENTRATION AND VIABILITY; (B)  
TRANSFECTION PERCENTAGES; (C)  VLPS PRODUCTION . 
  
B A 
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8.3  CELL CONCENTRATION AN D CELL CYCLE PHASE EFFECT  
 
In order to understand better the correlation between the healthy state of cells in the 
culture, their concentration and the cycle phase of the culture related to transfection 
and VLP production, data coming from independent replicates were deeply 
analyzed. 
 
Moreover, with the same aim, a further experiment was done. The growth curve 
of an inoculum of cells at the concentration of 0.3×106 cells/ml was followed by 
analyzing every 24 hours its cell concentration, viability and cell cycle phase. 
Every 24 h a volume of 20 ml was taken from the culture and separated into a new 
flask to be transfected. The experiment scheme is explained in  
Figure 19. Transfection was carried out without medium exchange. Cell growth, 
transfection percentages and VLP production of the separated and transfected 
volumes were quantified at 48 and 72 hpt. 
 
 
 
FIGURE 19  –  SCHEMATIC REPRESENTATION OF THE TRANSFECTION OF A VOLU ME COMING FROM A 
GROWTH CURVE. 
  
RESULTS A ND DISCUSSION  
47 
8.3.1  DEEPER DISC USSION OVE R C ELL C ONC ENTRATION  AT THE TIME-POINT 
OF TRANSFEC TION  
 
Analyzing the data shown in Figure 12, as it was expected, it can be noticed how a 
major quantity of positively transfected cells leads to higher concentrations of VLP 
in the supernatant, as it is described by Figure 20. 
 
 
FIGURE 20  - D IRECT CORRELATION BETWEEN POSITIVELY TRANSFECTED CELLS AND VLP PRODUCTION  
48  HPT. 
What could be thought, is that transfecting a higher concentration of cells should 
give as result a higher protein production; but this is not the case, as stated by the 
cell density effect, i.e. the drop in the specific productivity in the baculovirus-insect 
cells expression system when cells are infected at high cell densities which, 
actually, can be extended even to mammalian and in suspension cell cultures. So, if 
specific productivity can be maintained at its maximum level, increasing cell 
density improves volumetric production; unfortunately, it is well documented that 
insect cell lines currently used for protein production undergo a severe loss in 
specific productivity when infected at high cell densities (52) (53) (54). This effect 
is not so well described for mammalian cells and suspension cultures, while there 
are studies that relate the initial cell density and the specific growth in batch culture, 
where kinetics studies have been done to quantitatively analyze the reduced growth 
rates (55). The results of the experiment described in paragraph 8.3 can be traced to 
some sort of cell density effect and will be presented and described in the following 
paragraph. 
 
Transfected volumes were separated from a growing culture started with an 
inoculum, thus, every 24 h, i.e. the time the volume was separated to be immediately 
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transfected and cell concentration assessed, the cell concentration in the separated 
volume was higher. This means that every 24 h a denser culture was transfected. 
Positive transfected cell percentages were analyzed 48 and 72 hpt (which is also 48 
and 72 hours post volume separation). This allowed to relate transfection 
percentages and cell concentration. Results are shown in Figure 21. 
 
 
FIGURE 21  - PERCENTAGE OF GFP+  CELLS 48  HPT RELATED TO CELL CONCENTRATION AT TRANSFECTION  
TIME-POINT IN MILLION CELLS PER ML.  
 
As it can be noticed, the higher the cell concentration at the transfection time-point 
the lowest the percentage of positively transfected cells 48 and 72 hpt (72 hpt data 
are not shown, but the trend is maintained). Over ~ 4×106 cells/ml transfection 
percentages reach zero, thus there is no transfection. On the other hand, the highest 
transfection percentages are reached at very low cell concentrations, for example at 
~ 0.6×106 cells/ml around ¾ of cells in the culture are transfected. But, it is 
necessary to refer to the parameters of transfection and to the physiological state of 
the culture. The subtracted volume was always transfected with the same quantity 
of polyplexes (1µg/ml of DNA, cf. Materials and Methods), which can justify the 
high and the low transfection rates respectively. When cells are at a very low 
concentration, when the polyplexes are added into the culture, they are very 
available for cells, which can easily get in contact with them; as cells become more 
concentrated, the meeting between the two is always more difficult. But, this is not 
the only reason. High cells concentrations are achieved after days of incubation 
(typically the highest cell concentration is reached at the seventh day, cf. Figure 
11); this means that, as time passes, the culture gets older, accumulating waste 
products and housing cells entering a worst physiological state. 
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Due to the toxic effect of transfection and the metabolic effort necessary for VLP 
production, it appears not to be appropriate to transfect cells that do not show a 
good physiological state. This assumption is confirmed by the growth rates after 
transfection. In spite of the effort cells have to do after transfection, the growth rates 
are positive until the fourth day of transfection (cell concentration: ~ 2×106 cells/ml) 
and from the fifth are negative (data not shown). 
 
8.3.1.1 CELL PHYS IOLOGICAL CO NDITIONS-INDEPENDENT CELL 
DENS ITY EFFECT  
 
In order to analyze deeper the effect of polyplexes availability and the physiological 
condition of cells, the following experiments were designed. 
 
An appropriate volume of cells was expanded to the concentration of 2×106 
cells/ml, than cells were concentrated at 2, 3 and 4 ×106 cells/ml and transfected 
with standard and higher final DNA concentration (respectively 1 and 3 µg/ml). An 
alternative transfection protocol was followed too. This protocol has been proposed 
by Bollin F. (56) and adapted to the conditions used in this work: an appropriate 
culture volume was centrifuged, keeping in mind that the final volume of 
transfection was 20 ml, and the cell pellet was gently re-suspended in the 
transfection mix, transferred in a flask containing 50% of pre-warmed fresh culture 
medium. Cell culture was than incubated under agitation for 1 h and the other half 
of medium was added. Using this second transfection protocol, cells were 
concentrated at 4×106 cells/ml and separately transfected with a final DNA 
concentration of 1 and 3 µg/ml. These two experiments are schematically explained 
in Figure 22. 
 
 
FIGURE 22  –  SCHEMATIC REPRESENTATION OF THE EXPERIMENTS DONE TO ASSESS THE CELL DENSITY  
EFFECT INDEPENDENTLY FROM THE PHYSIOLOGICAL CELL STATE. WAY (A), CONCENTRATION AND  
TRANSFECTION EXPERIMENTS. WAY (B)  “BOLLIN METHOD”  EXPERIMENTS .  
A 2×106 cells/ml culture was concentrated in order to reach higher concentration 
levels but with cells which physiological conditions were the same as in the 
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standard protocol and thus separate the effects of cell concentration and 
physiological state of the culture. The higher quantities of DNA used for the 
polyplexes formation permitted to be sure that polyplexes concentration was 
enough to transfect even really high cell concentrations. The expected effect of the 
so called “Bollin method” was to force contact between cells and polyplexes, thus 
increasing transfection rates. Results are shown in Figure 23. 
 
 
FIGURE 23  - POSITIVELY TRANSFECTED CELL PERCENTAGES ARE SHOWN 48 AND 72 HPT. (A)  SHOWS THE 
RESULTS OF THE TRANSFECTION DONE FOLLOWING THE STANDARD PROTOCOL, CONCENTRATING CELLS 
AND USING TWO DIFFERENT FINAL CONCENTRATIONS OF DNA FOR THE PREPARATION OF THE 
POLYPLEXES. (B)  SHOWS THE TRANSFECTION RESULTS OBTAINED WITH THE “BOLLIN METHOD”. (C)  AND  
(D)  SHOW THE VLP PRODUCTION RESPECTIVELY OBTAINED THROUGH THE STANDARD AND THE BOLLIN  
PROTOCOL. 
As it is shown in Figure 23A, the highest transfection percentages are reached only 
strictly following the standard protocol, where there is no actual cell concentration 
and the final DNA concentration is 1 µg/ml. Using higher DNA concentrations 
doesn’t mean to transfect more cells, as long as cell concentrations are not really 
high (2 and 3×106 cells/ml). In fact, comparing transfection percentages, those are 
lower as DNA quantity is increased but cell density is maintained constant, 
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probably due to a toxic effect of DNA on cells, as, if viability of cells after 
transfection is compared (data not shown), it can be noticed a higher decreasing rate 
of viability when cells are transfected with 3 µg/ml DNA. This means that, as DNA 
quantity is increased, the living cells concentration after time-point post-
transfection decreases, resulting in a lower living cell transfected population. 
 
This is not true when cells concentrated at 4×106 cells/ml are transfected. Using 
higher DNA concentration a larger percentage of cells is transfect, compared to 
cells transfected with 1 µg/ml DNA. However, transfection percentages are 
generally lower than those reached transfecting cells at lower concentrations. This 
could be because the quantity of polyplexes used to transfect cell at these high 
concentrations is not sufficient to reach higher transfection percentages or because 
the polyplexes are not available for cells in the culture medium. 
 
The results obtained using the “Bollin method” are shown in Figure 23B. The 
percentage of GFP+ cells transfected using the “Bollin method” is comparable to 
the percentage of GFP+ cells reached when following the standard protocol. Cells 
transfected using the “Bollin method” and a DNA final concentration of 1 µg/ml 
almost weren’t transfected (transfection percentages are around 5% at 48 as well as 
at 72 hpt), but, by increasing DNA concentration, higher transfection percentages 
are reached. So, if cells are concentrated to 4×106 cells/ml and transfected with a 
final DNA concentration of 3 µg/ml following the “Bollin method”, transfection 
percentages reach 60% 72 hpt and are comparable to the results obtained using the 
standard protocol. 
 
The quantity of VLP production is shown in Figure 23C and D. As production is 
directly related to transfection percentages, as, assuming that each cell has got more 
or less the same specific productivity, the more cells are transfected the higher will 
be the production; these data mirror the result just described. It has to be noticed 
that the relative fluorescence of the supernatant of the culture of cells concentrated 
and transfected with the “Bollin method” and with the higher DNA concentration 
is the highest among all. This is because volumetric productivity depends on cell 
density that here is the highest, so, even if the transfection percentage is comparable 
with the one reached following the very standard protocol, VLP production reached 
is higher. 
 
Thus, it has been demonstrated that cell concentration has a big effect on 
transfection and production and that, by transfecting higher cell concentrated 
cultures, it is possible to reach a higher production. As some cell density effect 
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appears, it is possible to avoid it by concentrating cells that are in an active and 
healthy state and by forcing polyplexes of transfection entering cells. VLP 
production was also improved, increasing the fluorescence of the culture 
supernatant harvested 72 hpt of around twenty-five arbitrary units, which means an 
increment of production of ~ 2.5 µg/ml. 
 
8.3.2  DEEPER DISC USSION OVE R C ELL C YC LE PHASE  
 
The effect of cell cycle phase over transfection and VLP production was studied 
too. As already introduced, cell cycle phase may influence the transfection 
efficiency. The cell cycle analysis of the data presented in Figure 12 was therefore 
performed. As observed in Figure 24 a direct correlation between the cell cycle 
phase and the transfection percentage could be observed, so, the higher the 
percentage of cells in G2/M phase at the time-point of transfection, the higher the 
percentage of transfected cell. 
 
 
FIGURE 24  - CORRELATION BETWEEN CELLS IN G2/M  PHASE PERCENTAGE OF CELLS IN THE CULTURE AND 
TRANSFECTION PERCENTAGE 48  HPT. 
These data are also in agreement with those obtained in the experiment described 
in paragraph 8.3 and shown in Figure 25, but here, as already described, some cell 
density effect has to be taken into account. 
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FIGURE 25  - RESULTS IN TRANSFECTION PERCENTAGES RELAT ED BOTH TO CELL CYCLE PHASE OF THE 
CULTURE AND TO CELL CONCENTRATIONS .  
In order to analyze the cell cycle phase effect, two different cell cultures were 
blocked in two specific cycle phases using two different reagents. As control, the 
cell cycle phase of a normal, i.e. non-blocked and asynchronous, cell culture was 
analyzed starting from a culture inoculum. 
 
In a normal inoculum, cells are usually divided into phases as the followings: ~ 35% 
G0/G1 phase, ~ 15% G2/M phase and ~ 50% S phase. As cell culture grows, G2/M 
phase cell percentages reach a peak around 20% at the third day, than low down 
and S phase percentages increase as cell culture moves to death phase.  
 
 
GRAPH 1- (A)  SHOWS THE TYPIC AL CYCLING PROFILE OF A CULTURE THROUGH ALL ITS GROWTH ,  
STARTING WITH AN INOCULUM AT THE CONCENTRATION OF 0.3×106  CELLS/ML. (B) SHOWS THE PHASES 
PROFILE FOR 24 H OF A 2×106  CELLS/ML CULTURE 
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Nocodazole and Hydroxyurea were use to block cell division and to obtain two 
different blocked cell cultures. Previously cytotoxicity was determined and the 
kinetics of cell cycle blocking was followed. As last, after-drug-removal kinetics 
were followed. 
 
Results showed that: 
 
- Nocodazole has to be added at a final concentration of 2 µg/ml and cells 
have to be incubated with for 26 h to reach the maximum blocking effect 
and have a culture were ~ 86% of cells are in G2/M phase; 
- Hydroxyurea final concentration has to be 1.25 mM and incubation time 24 
h as to have a ~ 75% G0/G1 cell culture; 
- In both cases, drug removal is simply possible by complete medium 
exchange and flask change; after that, cells recover from the effect and start 
to divide again, but, only in the case of Hydroxyurea a synchronized cell 
culture is obtained (in the case of Nocodazole cells slowly leave G2-M 
phase). 
 
8.3.2.1 NOCODAZOLE CYTOTOXICIT Y ,  EFFECT AND WHOLE CULTURE 
BLOCKING  
 
Nocodazole cytotoxicity was studied by incubating cells in 96 well plates at 
different drug concentrations performing an MTT assay. Results are illustrated in 
Figure 26. Calculated ranges for Nocodazole were 0-5 µg/ml as final concentration 
and are in agreement with bibliography data (57).  
 
 
FIGURE 26  - NOCODAZOLE TOXICITY EXPERIMENT RESULT.  
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Four Nocodazole concentrations among the range were tested to know which has 
the major effect. So, cells were amplified at a final concentration of 2×106 cells/ml 
and incubated with 0 (as control), 0.2, 2 and 5 µg/ml Nocodazole for 12 h. After the 
incubation time, cell cycle phase analysis was performed. Results are shown in 
Figure 27. The major blocking effect is reached when 2 µg/ml Nocodazole are 
added to the culture, so that the major percentage of cells is blocked in G2/M phase. 
 
FIGURE 27  - DIFFERENT NOCODAZOLE CONCENTRATIONS RELATED TO THEIR EFFECT OVER CELL CYCLE 
PHASE  
To know the blocking profile, a culture of 2×106 cells/ml was blocked using 2 µg/ml 
Nocodazole and cell cycle was analyzed every hour for 24 h. The blocking profile 
curve is shown in Figure 28. 
 
FIGURE 28  - CYCLE PHASE PROFILE OF CELLS BLOCKED WITH NOCODAZOLE. 
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It can be noticed that Nocodazole blocks cells in G2/M phase but at 24 h the 
percentage is not stabilized into a constant value. Thus, a second experiment was 
done, incubating cells for a longer time and analyzing the cell cycle every hour but 
between 24 and 33 h post Nocodazole addition. Results show that after 26 h the 
percentages stabilize as G0/G1 and S percentages reach zero and G2/M percentage 
is now stable (data not shown). 
 
8.3.2.2 CELL CYCLE DEREGULATI ON AFTER NOCODAZOLE CYCLE 
BLOCKING  
 
In order to know the profile of cells cycling after having been blocked with 
Nocodazole, cell cycle phase of an enriched culture has been analyzed after drug 
removal. An appropriate volume of cell culture was expanded to the concentration 
of ~ 2×106 cells/ml and incubated for 26 h with 2 µg/ml Nocodazole, medium 
exchange and flask change were than performed and culture deregulation followed 
by cycle phase analysis every hour until 57 hpmc (hours post medium exchange). 
Figure 29 illustrates the cycling profile of the culture that does not appear to be 
synchronized. After 9 hpmc cells recover from the blocking effect and start to cycle 
by slowly leaving G2/M phase and entering G1/G0 phase and thus S phase. Around 
33 hpmc the culture stabilizes and start to have the normal cycle phase profile. 
 
 
FIGURE 29  - CELL CYCLE DEREGULATION AFTER NOCODAZOLE REMOVAL.  
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8.3.2.3 HYDROXYUREA CYTOTOXICITY ,  EFFECT AND WHOLE CULTURE 
BLOCKING  
 
Usually (58), Hydroxyurea is added to cell cultures in a concentration between 2 
and 4.3 mM, but the effect might be different among cell types. To assess the 
cytotoxic effect of Hydroxyurea over HEK293 cells a wide range of concentrations 
has been tested. Firstly the MTT assay was performed and resulted that at very low 
drug concentrations (until 0.5 mM), Hydroxyurea seems not to have any effect over 
cells; until 110 mM no toxic effect appears. A considerable toxic effect appears 
over 1 M drug concentration. 
 
As 1 M is a very high drug concentration, another set of drug concentrations was 
tested to assess which among the used (referring to bibliography data) has the minor 
cytotoxic effect at long time after addition. Thus, cells were expanded to ~ 2×106 
cells/ml in 6 well plates and Hydroxyurea was added to the culture at the 
concentrations of 1.25, 2.50, 3.75 and 5 mM. After 23 h incubation, cells viability 
was determined. There is no considerable cytotoxic effect even after longer times 
of exposure. 
 
 
FIGURE 30  –  (A)  HYDROXYUREA MTT  ASSAY RESULTS. INNER GRAPH ZOOMS BETWEEN 0  AND 25  MM  
CONCENTRATIONS OF HYDROXYUREA. (B) VIABILITY OF CELLS AFTER 23  H OF INCUBATION WITH 
HYDROXYUREA. 
 
The Hydroxyurea effect over cell cycle phase of the culture has been tested. Cells 
were expanded to ~ 2×106 cells/ml in 6 well plates and Hydroxyurea was added to 
the culture at five chosen concentrations (1.25, 2.50, 3.75, 5.00 and 100.00 mM). 
Cells were than incubated and cell cycle phase of the culture was analyzed 10 and 
23 hours post drug addition (hpp) to determine the blocking effect of the drug in 
comparison with a control culture where no Hydroxyurea was added (Figure 31). 
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FIGURE 31  –  HYDROXYUREA EFFECT OVER CYCLE PHASE. 
 
By the addition of Hydroxyurea, cells are blocked in G0/G1 phase so the culture is 
enriched of this kind of cells as time passes. As there is no toxic effect at these drug 
concentrations, viability doesn’t drop down but cell concentration does not 
increase, as cells are unable to divide. The major effect is reached using a 
concentration of 1.25 mM, so this will be the concentration used on every further 
experiment. 
 
To find the incubation time necessary to have a sufficiently enriched culture, an 
appropriate volume of cell culture was expanded to the concentration of ~ 2×106 
cells/ml and 1.25 mM Hydroxyurea has was added. Every hour a sample was taken 
to analyze cell cycle phase. After 24 h a high percentage (75%) of G0/G1 blocked 
cells is reached. 
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FIGURE 32  – (A)  HYDROXYUREA BLOCKING CELL CYCLE PHASE PROFILE; (B) STARTING CULTURE CELL 
CYCLE PHASE PROFILE HISTOGRAM; (C)  FINAL (AFTER 24  H INCUBATION WITH HYDROXYUREA) CELL 
CULTURE PHASE PROFILE HISTOGRAM .  
 
8.3.2.4 CELL CYCLE DEREGULATI ON AFTER HYDROXYUREA CYCLE 
BLOCKING  
 
In order to know the profile of cells cycling after having been blocked with 
Hydroxyurea, the cell cycle phase of an enriched culture has been analyzed after 
drug removal. An appropriate volume of cell culture was expanded to the 
concentration of ~ 2×106 cells/ml and incubated for 24 h with 1.25 mM 
Hydroxyurea, medium exchange and flask change were than performed and culture 
deregulation followed by cycle phase analysis every hour until 25 hpmc and every 
two hours between 25 and 33 hpmc. The cycling profile is described in Figure 33. 
After 5 hpmc cells completely recover from the blocking effect and start to cycle 
synchronously. As they start leaving G0/G1 phase, enter S phase until a maximum 
percentage; so, leave this phase too and enter G2/M phase. A full cycle is done after 
21 hpmc, when the culture reaches a second maximum in G0/G1 phase, and 
synchronization is gradually lost, in fact, only 50% of cells is now in this phase. 
 
B 
C 
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FIGURE 33  –  SYNCHRONIZED CULTURE OBTAINED BY HYDROXYUREA CYCLYING PROFILE. NOTABLE 
TIMES ARE UNDERLINED WITH COLOURED SYMBOLS IN THE CELL CYCLE PHASE CURVES.  
 
There are four notable times in the curves: until 5 hpmc the maximum of cells in 
G0/G1 phase is present and at 4 hpmc (red symbol) cells recover from the drug 
effect, as they start to enter S phase; at 8 hpmc (yellow symbol) the maximum 
percentage of cells are in S phase (usually ~ 90%); at 13 hpmc (green symbol) cells 
reach the maximum in G2/M phase (~ 30%). At 10 hpmc (blue symbol) there isn’t 
any cell belonging to G0/G1 phase and this is the absolute minimum of the G0/G1 
percentage curve. 
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8.3.2.5 TRANS FECTION  TIMING  
 
Times involved in cell transfection can be a very interesting variable that has not 
been well studied yet and for the aims of this work it is important to know how long 
do the PEI/DNA polyplexes take to enter cells in suspension. Some previous work 
have tracked the pathway of PEI/DNA complexes for gene delivery into different 
kinds of cells; this has been possible through confocal microscopy, fluorescent 
labeled PEI and DNA and the expression of eGFP encoded in the reporter plasmid. 
Thus, it has been possible to track the entrance of both PEI and DNA into cells and 
also estimate the time needed for the reporter gene expression. The evidence is that 
by 30 min post transfection PEI/DNA complexes begin to attach to cell surfaces 
forming aggregates. Endocytosis of the complexes begins 2-3 hours post 
transfection and nuclear localization is common 3.5-4.5 hpt. After one more hour, 
the earliest transgene expression is observed (Figure 34) Thus, in this work a time 
of four hours was accepted as the time polyplexes take to enter cells. 
 
 
 
 
  
FIGURE 34  –  TRACKING OF DOUBLE-LABELED PEI/DNA COMPLEXES.  (A)  AT 2  HPT VISIBLE COMPLEXE S 
APPEAR AS CLUMPS ON THE CELL’S EXTER IOR , AS INDICATED BY ARROWS. (B) AT 3  HPT BOTH SURFACE 
AGGREGATION AND ENDOSOMES ARE VISIBLE .  THE ARROW INDICATES ENDOSOMAL FORMATION .  (C)  AT 
4  HPT ENDOSOMES ARE VISIBLE THROUGHOUT THE CELL CYTOPLASM . (D)  AT 4.5  HPT FLUORESCENT 
STRUCTURES CONTAINING BOTH PEI  AND DNA  IN SIDE THE CELL NUCLEUS ARE PRESENT. (BAR =  10  µM)  
(61) 
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8.3.2.6 ENRICHED CULTURE TRAN S FECTION 
 
After having obtained two specific cycle phase enriched cultures, drug removal was 
performed and cycling cultures were obtained. In order to study the cell cycle phase 
effect over transfection, these cell cultures were transfected. 
 
In the case of Nocodazole blocked cell culture, it is possible to take advantage only 
of the high percentage of cells in G2/M phase. So, the enriched culture was 
transfected 4, 6 and 8 hours before drug removal, to take the maximum possible 
advantage from the cycle phase effect. Another enriched culture was transfected 
right after medium exchange too. Such times were selected in order to permit the 
complete entrance of the PEI/DNA polyplexes into the cells and to lose, through 
medium exchange, the minor quantity of polyplexes that still were in the culture 
medium. 
 
An appropriate volume of cell was expanded to 2×106 cells/ml, incubated with 2 
µg/ml Nocodazole for 26 h and transfected at those precise time-points, medium 
exchange was performed before or after transfection as designed. A control culture 
without any Nocodazole addition was expanded and transfected as well. It was 
expected to obtain very high transfection percentages as polyplexes were forced to 
enter cell in G2/M phase. Results are summed in Figure 35. 
 
 
FIGURE 35  – (A)  TRANSFECTION OF CELLS RELEASED FORM NOCODAZOLE EFFECT; (B) TRANSFECTION OF 
THE CONTROL CULTURE . 
Generally, it was obtained a considerable transfection percentage even if 
transfection was made before medium exchange, indicating that polyplexes do enter 
cells in the interval time between transfection and medium exchange. There is no 
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difference between the samples transfected before and after medium exchange in 
the transfection percentages, confirming that even the shortest interval permits 
transfection. But, comparing these data between enriched and control culture, the 
transfection percentages of the enriched culture are considerably lower, which is in 
contrast with the expected. VLP production data reflect this trend, but also indicate 
that even if cells were blocked with Nocodazole, if they are transfected, they are 
able to produce VLPs. There must be some side effect within the cycle blocking 
effect of Nocodazole that does not permit cell transfection. 
 
In the case of Hydroxyurea, a synchronized culture was obtained. The culture was 
transfected at the four notable times selected in the deregulation curve (Figure 33), 
keeping in mind the four hours gap between the transfection of the culture and the 
actual time polyplexes enter cells (cf. paragraph 8.3.2.5). This is because polyplexes 
had to enter cells at the exact maximum peak, i.e. at each of the four notable times, 
in order to take the maximum advantage from the cell cycle phase effect. It was 
expected to observe the cell cycle phase effect differentiated through phases. 
 
Cells were expanded to 2×106 cells/ml, incubated with 1.25 mM Hydroxyurea for 
24 h, while a control culture was only expanded to the same concentration. Medium 
exchange was performed and the culture was transfected 1, 4, 6 and 9 hpmc. 
Transfection at 1 hpmc means that the polyplexes enter cells at 5 hpmc, when they 
recover from drug effect, restart to cycle and the maximum percentage of cells is in 
G0/G1 phase. Transfecting the culture 4 hpmc means that the polyplexes enter the 
cells at 8 hpmc, when the S phase peak is reached; 6 hpmc is equal to transfection 
at 10 hpmc when there is the minimum in G0/G1 phase and culture transfection 9 
hpmc is cell transfection 13 hpmc, at G2/M maximum peak. 
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FIGURE 36  –  RELATION BETWEEN POSITIVE TRANSFECTION PERCENTAGES, TIME AFTER DRUG REMOVAL 
AND CELL CYCLE PHASE . (A)  SYNCHRONIZED CULTURE DATA. (B)  CONTROL CULTURE DATA.   
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The observed results (Figure 36) show that the transfection percentage of the 
synchronized culture at the G2/M phase peak is not the highest. But there are some 
considerations that can be done. At the selected hpmc the cycle phase percentages 
are in agreement with those in the deregulation curve (Figure 33), meaning that four 
hours post culture transfection cell cycle phase is not affected by transfection and 
thus cells continue cycling as expected. 
 
Looking at the transfection percentages 48 hpt of the synchronized culture, it can 
be noticed that there is transfection at every chosen hpmc, which correspond to 
peaks in cell cycle phases percentages curve. GFP+ cell percentage is higher when 
cells in G0/G1 phase peak are transfected (5 hpmc, no cell in G2/M phase) and it is 
the lowest when cells in G2/M phase peak are transfected (13 hpmc). Then, it could 
be thought that transfection is completely independent from cell cycle phase. The 
control culture, i.e. the non-blocked and asynchronous culture, maintains such 
transfection profile. It has to be noticed also that cells are transfected at increasing 
hpmc. It can be noticed that the transfection percentages low down as time passes 
from medium exchange. It is probable that transfection percentages depend much 
more on culture physiological state after medium exchange than they do on cycle 
phase, leading to the obtained results. The lower transfection percentage has been 
obtained 13 hpmc, which is a considerable lack of time, while the highest 
transfection percentage is obtained transfecting cells only 5 hpmc. Moreover, 
transfection percentages at 5 hpmc of the synchronized culture are comparable to 
the percentages usually obtained following the standard protocol, where cells are 
transfected right after medium exchange. A last consideration can be done 
observing at the percentages of transfection on the synchronized culture 10 and 13 
hpmc. These two times are not so far from each other and are noticeably distant 
from medium exchange, and yet, the percentage of transfection 72 hpt of cells 
transfected 13 hpmc is significantly higher than those transfected 10 hpmc. As here 
we can ignore the time effect, the reason could lie in the 10% more of cells in G2/M 
phase in the 13 hpmc sample. Furthermore, this transfection percentage is 
comparable to the correspondent in the control culture, and so are the G2/M 
percentages. 
 
Medium exchange has a strong effect over transfection, and it can even shadow cell 
cycle phase effect. If its effect can be eliminated, it is still possible to notice the 
phase effect and that a major G2/M phase percentage leads to higher transfection 
percentages, as it was shown in the upper graph (Figure 24).
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The HEK293 cell line used in this work, cultured in suspension in supplemented 
FreeStyle at 37 °C and 5% CO2, can grow up exponentially until day six to a 
maximum concentration of 4.8×106 cells/ml, observed around 150 h after the stating 
inoculum. The maximum growth rate (µmax) is 0.021 h
-1 and the doubling time is 
33.2 h. 
 
The used standard transfection protocol states to transfect a cell culture in the 
exponential phase at the concentration of 2×106 cells/ml with a mixture of 
PEI:DNA 2:1, with DNA final concentration of 1 µg/ml, after medium exchange. 
Many variables have been tested independently to analyze the strength of such 
protocol. 
 
It resulted that cell positive transfection percentages and VLPs production are not 
affected by the mixture solvent used to prepare the PEI/DNA polyplexes (not-
supplemented or supplemented FreeStyle culture medium), nor if the medium is 
used cold, nor if the mixture is not well vortexed. Even the age of the flasks (meant 
as number of times a flask has undergone a cleaning and sterilization process) used 
is not affecting cell transfection, VLPs production nor cell growth. Thus, it can be 
concluded that the transfection protocol is robust and not affected by the operating 
factors. 
 
However, some of these variables have a considerable effect over cell growth and 
viability post transfection. Supplemented FreeStyle medium as solvent for the 
PEI/DNA mixture has a positive effect resulting in a slightly higher viability in the 
firsts hours after transfection, maybe because of the components used to supplement 
the medium. Cold mixture addition to the cell culture has a negative effect on 
viability, supposedly because it induces an adaptive response to cold in the firsts 
hours post transfection. 
 
It is generally known that transfection has a toxic effect on cells, caused by 
exogenous DNA and PEI toxicity and even by the same protocol, resulting in a 
percentage of cell death post transfection and extending doubling time. The addition 
of a rest time after medium exchange before transfection permits to increase cell 
concentration days post transfection, thus having a positive effect on viability but 
no considerable effect over transfection and VLP production. Due to such toxic 
effects, health cell state has to be considered too, thus it was considered it through 
the cell passage. It resulted that cells at really high passage (considering the 
maximum reachable passage around # 100) cannot be used as it results in the death 
of the culture; otherwise, cell passage has no considerable effect. 
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Cell concentration at transfection time-point is an important variable and it affects 
transfection and VLPs production. It resulted that the standard protocol is already 
optimized in its variables, as transfecting cultures with higher cell concentrations, 
even with higher quantities of DNA, did not result in more cell transfection or 
product production. Such results are in agreement with the cell density effect; this 
effect can be avoided by using an alternative transfection protocol referred as 
“Bollin method”, that forces contact between cells and polyplexes through cell re-
suspension in the PEI/DNA mixture. The Bollin method permitted to transfect a 
higher percentage of cells and obtain more VLPs production when exponential 
phase cells are concentrated at 4×106 cells/ml and transfected with a mixture of 
PEI/DNA polyplexes in which the final DNA concentration is 3 µg/ml. 
 
The cell cycle was monitored to see if it had any implication for efficient transfer 
of plasmid DNA molecule in the nuclear environment. Comparing many 
independent repetitions it is possible to show that cell transfection and G2/M phase 
are directly related, maybe because the lack of the lipid membrane in this cell cycle 
phase allows polyplexes to easily reach the nucleus. Therefore, two drugs were used 
(Nocodazole and Hydroxyurea) to synchronize a cell culture and monitor the cell 
cycle phase effect. Before using such components, their operating concentrations 
and times have to be assessed. So, it is shown that Nocodazole blocks cells in G2/M 
phase; its operation range is between 0 and 5µg/ml but has to be added to the cell 
culture at a final concentration of 2µg/ml to have the maximum blocking effect. 
After 26 hours of incubation with Nocodazole the percentage of cells in G2/M phase 
stabilizes reaching 100%. Hydroxyurea blocks cells in G0/G1 phase; it has no 
considerable toxic effect until 1 M final concentration and its maximum effect over 
cycle blocking is obtained at a final concentration of 1.25 mM. After 23 hours a 
sufficient percentage of cells (around 75%) is blocked in G0/G1 cell cycle phase. 
The effect over the exact percentage of cells blocked over time is dependent on the 
cell cycle phase profile of the starting culture, however, the results are reproducible. 
Drug removal is simply through medium exchange and flask change. After drug 
removal, Nocodazole blocked cells are not synchronized and slowly leave G2/M 
phase; after 33 hour post medium exchange the culture re-starts to cycle as a normal 
asynchronous one; while Hydroxyurea blocked cells are synchronized. 
Hydroxyurea synchronized cell culture shows the typical profile of a synchronized 
culture; after 21 hours a cycle is completed and the synchronization is gradually 
lost. Cell cycling profiles after drug removal are reproducible. 
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The locking in G2/M phase trough Nocodazole did not lead to higher transfection 
percentages, but to lower. Probably there is some side effect related to Nocodazole 
that does not permit transfection. The data obtained by the Hydroxyurea 
synchronized culture are not easy to explain, as a cell cycle effect is not evident. 
What was expected in both drug-threated cultures was a higher transfection 
percentage for a higher percentage in G2/M phase, but this was not the case. In the 
case of Hydroxyurea synchronized culture, results can be explained considering a 
strong effect of the medium exchange for drug removal; considerations done 
eliminating such effect, still directly relate G2/M phase to positive transfection. 
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Some improvements should be done looking back at results explained in this work 
with the aim to explain better the effects observed. 
 
As timing in the transfection of a synchronized culture is very important, it is 
necessary to know how much time take the polyplexes to enter the cells. Thus, the 
transfection of a normal culture will be observed under a confocal microscope. The 
reagents suggested for this experiment are the following: Hoechst 33342 for cell 
nucleus staining and Cell Mask deep red membrane stain as their fluorescence does 
not interfere with the fluorescence of the VLPs (where the Gag protein is fused to 
the eGFP) and are already available in the laboratory; and Cy3 to label pDNA. All 
this fluorescent probes do no interfere with each others as excitation and emission 
wavelength are quite different. This experiment will allow to know the exact timing 
of transfection and could be repeated with differently treated cells. The knowledge 
of this variable will permit to repeat those experiments where time is an essential 
variable. 
 
To eliminate the medium exchange effect from the transfection experiment of the 
Hydroxyurea synchronized culture, I propose to repeat the experiment exchanging 
the medium not only to release the culture from the drug effect but also right before 
transfection. As the same time will have been passed between medium exchange 
and transfection, the medium exchange effect could thus be eliminated, maybe 
allowing to see the underlying cell cycle phase effect. 
 
As further experiment to study the cell cycle effect, cells from a normal culture 
could be divided for their cycle phase using a cell sorter. Once divided, the new 
three cultures could be transfected and the cell cycle effect revealed. As control, a 
normal culture could be passed through the cell sorter without dividing it and then 
transfected. Cell sorting stresses cells, so the same good transfection percentages as 
those obtained following the standard protocol might not be seen, but, as every 
group will undergo the same treatment, such “stress variable” will result eliminated. 
 
As increasing DNA final concentration when transfecting cell at higher 
concentrations did not result in more transfection, PEI concentration for polyplexes 
formation should be optimized. Actually, this has been done by my work-mate 
Javier Fuenmayor and the results are explained it his thesis (59). Summarizing, 
through DoE, different DNA and PEI concentrations were elected, cell transfection 
was performed and data were analyzed through Sigma Plot 11.0. Results show that, 
for a standard transfection, PEI concentration should be increased to 3.3 leading to 
6% more transfection, comparing to standard conditions. 
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As there is evidence that G2/M cell cycle phase has a direct effect on positive 
transfection and thus on VLPs production, probably because of the lack of 
membranes during M phase, some reagents able to solubilize the cell membrane 
should be tested. This work was done by my work-mate Javier too and it is 
explained in his thesis (59). Dimethyl-sulfoxide (DMSO) and lithium acetate gave 
negative results; while the use substances that could improve the production gave 
good results. DMSO ant lithium acetate are able to depolarize the plasmatic 
membrane, while, volproic acid inhibits HDAC1, thus inhibits histone 
deacetilation, and trichostatin A modifies the binding of transcription factors to 
DNA. Through DoE Plackett-Burrman the concentration of volproic acid and 
trichostatin A where optimized to reach higher VLPs production. Both are able to 
increase transcription and thus VLPs production. If they are added at a final 
concentration of 6 mM and 0,04 nmol/ml respectively, right after transfection, the 
VLPs production can rise up to five times comparing to the normal level obtained. 
 
Once this proposed analysis will be completed, the mechanism of HEK293 transient 
transfection for the production of Gag-eGFP VLPs will be better understood, 
hopefully leading to more stable results. Thus, as partly already done, we could take 
advantage of most effective variable in order to obtain a more efficient transfection 
and a higher VLPs production. 
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